The FINANCIAL — Wyeth K.K. (Headquarters: Shinagawa-ku, Tokyo, President & Representative Director Michael Goettler, “WKK”), ASKA Pharmaceutical Co., Ltd (Headquarters: Minato-ku, Tokyo, President, Representative Director Takashi Yamaguchi, “ASKA”) and Takeda Pharmaceutical Company Limited (Headquarters: Chuo-ku, Osaka, President & CEO Yasuchika Hasegawa, “Takeda”) today announced changes to the Japanese distribution, sales and promotion for WKK’s transdermal absorption-type analgesic and anti-inflammatory agent, “SELTOUCH Pap 70, 140” (“SELTOUCH”). WKK and ASKA signed an agreement in which the sales right for SELTOUCH is granted to ASKA. ASKA and Takeda also signed an agreement in which the sales and promotion of SELTOUCH are entrusted to Takeda.
Under these agreements, Takeda will assume promotion of SELTOUCH, starting October of this year, while continuing the sales to wholesalers.
WKK has been focusing on key strategic products in the areas of rheumatoid arthritis, oncology and hematology, and vaccines, and along with this strategy the company has given consideration to which company to entrust sales and promotion of SELTOUCH to, and has agreed to grant the sales right for SELTOUCH to ASKA. Through this agreement, it becomes possible for WKK to strengthen activities for its key strategic products.
Meanwhile, since promotional activities of ASKA are limited in the orthopedic surgery area, in which SELTOUCH is mainly prescribed, it has decided to entrust promotion to Takeda, focusing on the physical distribution of SELTOUCH to Takeda.
Takeda has a solid foundation in the area of orthopedic surgery through the promotion of the therapeutic agents “Enbrel” for rheumatoid arthritis which it co-promotes with WKK, and “Benet” for osteoporosis. Takeda will further increase its presence in this area through the promotion of SELTOUCH.
Discussion about this post